Arrowhead starts triple-combo hepatitis B test, triggering J&J payday

Arrowhead Pharmaceuticals has added a triple-combination arm to its chronic hepatitis B virus clinical trial. The cohort will assess ARO-HBV in combination with two undisclosed drugs selected by Johnson & Johnson.